Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeff D Johnson

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 28, 2023
Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitisYun-Jung Choi, Jeff D Johnson, Jin-Ju Lee, et al.
PPAR Research|April 14, 2025
Single and Multiple Doses of Seladelpar Decrease Diurnal Markers of Bile Acid Synthesis in MiceEdward E Cable, Jeffrey W Stebbins, Jeff D Johnson, et al.
Hepatology (Baltimore, Md.)|December 20, 2023
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitisAndreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
American Journal of Physiology. Gastrointestinal and Liver Physiology|November 28, 2023
Seladelpar combined with complementary therapies improves fibrosis, inflammation, and liver injury in a mouse model of nonalcoholic steatohepatitisYun-Jung Choi, Jeff D Johnson, Jin-Ju Lee, et al.
PPAR Research|April 14, 2025
Single and Multiple Doses of Seladelpar Decrease Diurnal Markers of Bile Acid Synthesis in MiceEdward E Cable, Jeffrey W Stebbins, Jeff D Johnson, et al.
Hepatology (Baltimore, Md.)|December 20, 2023
Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitisAndreas E Kremer, Marlyn J Mayo, Gideon M Hirschfield, et al.
Pageof 1